Dynavax Technologies Investigated for Sale to Sanofi at $15.50 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
- Transaction Investigation: Kahn Swick & Foti LLC is investigating the proposed sale of Dynavax Technologies to Sanofi, where shareholders are set to receive $15.50 per share, raising questions about whether this price adequately reflects the company's true value.
- Legal Rights Consultation: Shareholders who believe the transaction undervalues Dynavax can seek no-obligation legal advice from Kahn Swick & Foti, aimed at protecting their rights and ensuring transparency in the sale process.
- Transaction Structure: The acquisition is structured as a tender offer, indicating that timing may be critical, and shareholders need to respond promptly to safeguard their interests.
- Former Attorney General Involvement: The involvement of former Louisiana Attorney General Charles C. Foti, Jr. in this investigation underscores the law firm's commitment to scrutinizing the transaction and advocating for shareholder rights.
DVAX
$15.385+Infinity%1D
Analyst Views on DVAX
Wall Street analysts forecast DVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DVAX is 21.00 USD with a low forecast of 11.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 15.370
Low
11.00
Averages
21.00
High
32.00
Current: 15.370
Low
11.00
Averages
21.00
High
32.00
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
